Personal information

Emails & domains

Verified email addresses

Verified email domains

Activities

Collapse all

Employment (5)

Vanderbilt University: Nashville, US

2024-08-05 to present | Assistant Professor (Molecular Physiology and Biophysics)
Employment
Source: Self-asserted source
Stephanie A. Wankowicz

University of California San Francisco: San Francisco, CA, US

2023-03-01 to 2024-08-01 | Assistant Professional Researcher (Bioengineering and Therapeutic Sciences )
Employment
Source: Self-asserted source
Stephanie A. Wankowicz

Dana Farber Cancer Institute: Boston, MA, US

2018-03-01 to 2018-06-30 | Computational Biologist (Medical Oncology)
Employment
Source: Self-asserted source
Stephanie A. Wankowicz

Dana Farber Cancer Institute: Boston, MA, US

2017-05-01 to 2018-03-01 | Associate Computational Biologist (Medical Oncology)
Employment
Source: Self-asserted source
Stephanie A. Wankowicz

Dana Farber Cancer Institute: Boston, MA, US

2013-06-01 to 2016-05-01 | Senior Research Data Specialist (Medical Oncology)
Employment
Source: Self-asserted source
Stephanie A. Wankowicz

Education and qualifications (2)

University of California San Francisco: San Francisco, CA, US

2018-09-01 to 2023-03-01 | Graduate Student (Biophysics)
Education
Source: Self-asserted source
Stephanie A. Wankowicz

University of Massachusetts Amherst: Amherst, MA, US

2009-09-01 to 2013-05-01 | Undergraduate Student (Biochemistry and Molecular Biologist)
Qualification
Source: Self-asserted source
Stephanie A. Wankowicz

Works (23)

Publisher Correction: The long tail of oncogenic drivers in prostate cancer.

Nature genetics
2019-07-01 | Journal article
DOI: 10.1038/s41588-019-0451-6
PMID: 31152158
Source: Self-asserted source
Stephanie A. Wankowicz

Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2019-06-28 | Journal article
DOI: 10.1158/1078-0432.ccr-19-0908
PMID: 31253631
Source: Self-asserted source
Stephanie A. Wankowicz

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

The Journal of clinical investigation
2018-11-01 | Journal article
DOI: 10.1172/JCI125184
PMID: 30382943
PMC: PMC6205373
Source: Self-asserted source
Stephanie A. Wankowicz

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

British journal of cancer
2018-09-17 | Journal article
DOI: 10.1038/s41416-018-0261-0
PMID: 30220708
Source: Self-asserted source
Stephanie A. Wankowicz

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.

Nature genetics
2018-08-27 | Journal article
DOI: 10.1038/s41588-018-0200-2
PMID: 30150660
PMC: PMC6119118
Source: Self-asserted source
Stephanie A. Wankowicz

Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis.

Urologic oncology
2018-08-20 | Journal article
DOI: 10.1016/j.urolonc.2018.07.012
PMID: 30139659
Source: Self-asserted source
Stephanie A. Wankowicz

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."

Urologic oncology
2018-05-30 | Journal article
DOI: 10.1016/j.urolonc.2018.05.011
PMID: 29859727
Source: Self-asserted source
Stephanie A. Wankowicz

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

Cancer immunology research
2018-05-10 | Journal article
DOI: 10.1158/2326-6066.cir-17-0475
PMID: 29748390
Source: Self-asserted source
Stephanie A. Wankowicz

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

British journal of cancer
2018-04-20 | Journal article
DOI: 10.1038/s41416-018-0064-3
PMID: 29674707
PMC: PMC5943584
Source: Self-asserted source
Stephanie A. Wankowicz

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.

Clinical genitourinary cancer
2018-04-06 | Journal article
DOI: 10.1016/j.clgc.2018.03.016
PMID: 29706503
Source: Self-asserted source
Stephanie A. Wankowicz

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Science
2018-02-16 | Journal article
DOI: 10.1126/science.aan5951
Part of ISSN: 0036-8075
Part of ISSN: 1095-9203
Source: Self-asserted source
Stephanie A. Wankowicz

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer

Nature Communications
2017-12 | Journal article
DOI: 10.1038/s41467-017-02320-7
Part of ISSN: 2041-1723
Source: Self-asserted source
Stephanie A. Wankowicz

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Clinical genitourinary cancer
2017-08-02 | Journal article
DOI: 10.1016/j.clgc.2017.07.012
PMID: 28864222
Source: Self-asserted source
Stephanie A. Wankowicz

Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.

Cancer
2017-07-25 | Journal article
DOI: 10.1002/cncr.30907
PMID: 28743155
Source: Self-asserted source
Stephanie A. Wankowicz

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations.

Cancer discovery
2017-05-17 | Journal article
DOI: 10.1158/2159-8290.CD-16-0960
PMID: 28515055
PMC: PMC5836784
Source: Self-asserted source
Stephanie A. Wankowicz

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.

The Journal of urology
2017-05-06 | Journal article
DOI: 10.1016/j.juro.2017.04.102
PMID: 28487100
Source: Self-asserted source
Stephanie A. Wankowicz

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research
2017-01-30 | Journal article
DOI: 10.1158/1078-0432.CCR-16-2520
PMID: 28137924
PMC: PMC5511570
Source: Self-asserted source
Stephanie A. Wankowicz

Cancer immunotherapy: new applications in urologic oncology.

Current opinion in urology
2016-11-01 | Journal article
DOI: 10.1097/mou.0000000000000337
PMID: 27584023
Source: Self-asserted source
Stephanie A. Wankowicz

Letter to the Editor, Re: van der Heijden AG, Mengual L, Lozano JJ, Ingelmo-Torres M, Ribal MJ, Fernández PL, Oosterwijk E, Schalken JA, Alcaraz A, Witjes JA. A five-gene expression signature to predict progression in T1G3 bladder cancer. Eur J Cancer. 2016; 64:127-136.

European journal of cancer (Oxford, England : 1990)
2016-10-30 | Journal article
DOI: 10.1016/j.ejca.2016.09.017
PMID: 27806880
Source: Self-asserted source
Stephanie A. Wankowicz

Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.

BJU international
2016-10-26 | Journal article
DOI: 10.1111/bju.13674
PMID: 27700015
Source: Self-asserted source
Stephanie A. Wankowicz

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.

Scientific reports
2016-06-10 | Journal article
DOI: 10.1038/srep27702
PMID: 27283319
PMC: PMC4901342
Source: Self-asserted source
Stephanie A. Wankowicz

Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.

Clinical genitourinary cancer
2016-05-12 | Journal article
DOI: 10.1016/j.clgc.2016.05.001
PMID: 27262369
Source: Self-asserted source
Stephanie A. Wankowicz

Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles.

Nature medicine
2016-04-25 | Journal article
DOI: 10.1038/nm.4085
PMID: 27111282
Source: Self-asserted source
Stephanie A. Wankowicz
How many people are using ORCID?